Moderna, Inc. (NASDAQ: MRNA) has reported a narrower net loss for the fourth quarter of fiscal 2025, when the pharmaceutical company’s revenues declined.
- Fourth-quarter revenue totaled $678 million, down 30% from the corresponding quarter of fiscal 2024
- The sales decline primarily reflects lower COVID vaccine volume compared to the prior-year period
- The company reported a net loss of $826 million for the fourth quarter, compared to a loss of $1.1 billion in the prior-year quarter
- On a per-share basis, Q4 loss was $2.11, compared to $2.91 in the prior-year quarter
- The management targets full-year 2026 revenue to be up 10% from 2025; it sees the revenue split to be 50% U.S. and 50% internationally
- Costs of sale are expected to be approximately $0.9 billion in fiscal 2026
- Management is looking for research and development expenses of around $3.0 billion for FY26
- The guidance for full-year selling, general, and administrative expenses is around $1.0 billion
- Year-end cash and investments for 2026 are projected to be $5.5-6.0 billion